Prevalence, Determinants and Outcomes of Intravenous-to-Oral Switch of Antibiotic Therapy in Hospitalized Adults With Bloodstream Infection: Secondary Analysis of a Multicenter Cohort
Open Forum Infectious Diseases · 2026-10-31 · 13 (11)
DOI: 10.1093/ofid/ofag666 ↗Abstract
Abstract Background Intravenous-to-oral switch (IVOS) is considered safe in selected patients with bloodstream infection (BSI) and provides operational advantages. Still, it is underused in many clinical settings. We evaluated IVOS patterns, associated factors, and clinical outcomes in patients with BSI. Methods Secondary data were analyzed from 2 prospective, multicenter cohort studies recruiting patients with BSI. IVOS was assessed on day 3 and 7 after positive blood culture. Eligibility for IVOS was based on infectious focus, clinical safe-switch criteria, and antimicrobial susceptibility. Risk factors for non-IVOS were studied using multivariable logistic regression. Results Among 3824 patients, 2770 were included in the secondary analysis, and 742 (19.4%) were eligible and evaluable for IVOS. By day 7, 240 patients (32.3%) underwent IVOS. Switch occurred on the day of discharge in 107 patients (44.6%), and 1 day before discharge in 46 (19.2%). The most commonly used oral agents were ciprofloxacin (75 patients [31.3%]), sultamicillin (56 [23.3%]), and cefuroxime axetil (27 [11.3%]). Barriers to IVOS on multivariable analysis included diabetes (odds ratio, 0.57 [95% confidence interval, .38–.88]; P = .01), chronic kidney disease (0.64 [.41–.99]; P = .048), Pitt bacteremia score ≥2 on day 3 (0.43 [.19–.97]; P = .04), and septic shock before day 7 (0.31 [.11–.87]; P = .03), while urogenital focus (2.22 [1.50–3.28]; P < .001) and 2 study centers were positively associated with IVOS. IVOS was associated with shorter length of stay (7 vs 12 days; P < .001) and a lower 28-day mortality rate. Conclusions In clinically stable patients with BSI, IVOS was infrequently implemented. Barriers to IVOS should be addressed as part of antimicrobial stewardship programs.
EUVIMED